Breaking News

Tweet TWEET

Rosetta Genomics Receives 25th U.S. Patent Allowance

             Rosetta Genomics Receives 25th U.S. Patent Allowance

Award Strengthens Growing Portfolio of microRNAs in Viral Infection

PR Newswire

PHILADELPHIA and REHOVOT, Israel, March 18, 2013

PHILADELPHIA and REHOVOT, Israel, March 18, 2013 /PRNewswire/ --Rosetta
Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of
microRNA-based molecular diagnostics, announces receipt of a Notice of
Allowance from the U.S. Patent Office related to U.S. Patent Application No.
12/517,760 entitled "Nucleic Acids Involved in Viral Infection."

The allowed claims include a method of reducing the amount of virus
replication in a target cell infected with the virus by introducing into the
target cell an effective amount of miR-210, its variants or its precursor.

"We are delighted to add this new patent to our expanding intellectual
property portfolio of microRNAs in viral infection. This newly granted patent
further solidifies our dominant patent position in microRNAs and opens up
other disease states where microRNAs may be of great benefit. Many of the
current viral therapeutics suffer from low efficacy, toxicity and induction of
resistance. With its potential to reduce viral replication, miR-210 may prove
to be an effective therapeutic that may overcome the limitations of currently
available viral treatments," stated Kenneth A. Berlin, President and CEO of
Rosetta Genomics. "Our growing patent position in microRNAs provides us with
the opportunity to license, partner or otherwise derive value from this
powerful technology in viral and other disease areas."

Rosetta Genomics maintains a robust intellectual property strategy to protect
its leadership position in microRNA technology. Rosetta's portfolio includes
29 issued patents, including 25 in the U.S. In addition, Rosetta has 41
patent applications, including 21 in the U.S.

About miRview^® Products
miRview^® are a series of microRNA-based diagnostic products offered by
Rosetta Genomics. miRview^® mets² accurately identifies the primary tumor type
in primary and metastatic cancer including CUP. miRview^® meso diagnoses
mesothelioma, a cancer connected to asbestos exposure. miRview^® lung
accurately identifies the four main subtypes of lung cancer using small
amounts of tumor cells. miRview^® kidney accurately classifies the four most
common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC,
chromophobe RCC and oncocytoma. miRview^® tests are designed to provide
objective diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta
Genomics estimates that 200,000 patients a year may benefit from the miRview^®
mets² test, 60,000 from miRview^® meso, 54,000 from miRview^® kidney and
226,000 patients from miRview^® lung. The Company's assays are offered
directly by Rosetta Genomics in the U.S., and through distributors around the
world. For more information, please visit www.mirviewdx.com. Parties
interested in ordering the test can contact Rosetta Genomics at (215) 382-9000
ext. 309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular
diagnostics. Founded in 2000 Rosetta's integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic tools.
Rosetta's miRview® product line is commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan
recognized Rosetta Genomics with the 2012 North American Next Generation
Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations,
plans and prospects, including without limitation, statements relating
toRosetta'sstrategic plan,Rosetta's development or commercialization of
therapeutic assets, the market acceptance of Rosetta's
miRview^®assays,particularly miRview^®mets^2,Rosetta's capitalization of
its microRNA platform, Rosetta's patent positionand Rosetta's development of
personalized medicine productsconstitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various important factors,
including those risks more fully discussed in the "Risk Factors" section of
Rosetta's Annual Report on Form 20-F for the year ended December 31, 2011as
filed with the SEC. In addition, any forward-looking statements represent
Rosetta's views only as of the date of this release and should not be relied
upon as representing its views as of any subsequent date. Rosetta does not
assume any obligation to update any forward-looking statements unless required
by law.

Company Contact:              Investor Contacts:
Rosetta Genomics              LHA
Ken Berlin, President & CEO   Anne Marie Fields
(215) 382-9000, ext. 326      (212) 838-3777
investors@rosettagenomics.com afields@lhai.com
                              or
                              Bruce Voss
                              (310) 691-7100
                              bvoss@lhai.com

SOURCE Rosetta Genomics Ltd.